Patents Assigned to National University Corporation Chiba University
-
Publication number: 20210179773Abstract: A composition for forming a metallic luster film, includes: a thiophene polymer, in which a total content of an Fe atom, a Cu atom, an Mn atom, a Cr atom, and a Ce atom in the composition for forming a metallic luster film is 1500 ppm or less with respect to the thiophene polymer.Type: ApplicationFiled: December 8, 2020Publication date: June 17, 2021Applicants: FUJI XEROX CO., LTD., NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Wataru YAMADA, Satoya SUGIURA, Katsuyoshi HOSHINO, Rihito TAMURA, Kenta HORIKOSHI, Minako TACHIKI
-
Publication number: 20210170058Abstract: The present invention relates to a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and provides a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.Type: ApplicationFiled: April 15, 2019Publication date: June 10, 2021Applicants: NIHON MEDI-PHYSICS CO., LTD., National University Corporation Kagoshima University, National University Corporation Chiba UniversityInventors: Shota KOMOTO, Yu OGAWA, Yoshinari SHOYAMA, Tadashi HATANO, Yuji ITO, Yasushi ARANO, Hiroyuki SUZUKI, Tomoya UEHARA
-
Patent number: 11008388Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: GrantFiled: March 19, 2019Date of Patent: May 18, 2021Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori Hashimoto, Toshihide Yamashita
-
Patent number: 10980789Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.Type: GrantFiled: October 23, 2019Date of Patent: April 20, 2021Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Hiroyuki Nakamura, Toshihiko Murayama
-
Publication number: 20210106612Abstract: The present invention provides a target gene transcriptional repression inhibitor that can be designed in a sequence-specific manner, a composition containing the same, and use thereof. More specifically, the present invention provides a composition for use in inhibiting repression of gene expression by DNA methylation in a living subject, comprising pyrrole imidazole polyamide or a conjugate of pyrrole imidazole polyamide and a histone modifying enzyme inhibitor, wherein the pyrrole imidazole polyamide or the conjugate of pyrrole imidazole polyamide and a histone modifying enzyme inhibitor is designed so as to bind in a sequence-specific manner to a minor groove of promoter region DNA of the gene.Type: ApplicationFiled: February 1, 2017Publication date: April 15, 2021Applicant: National University Corporation Chiba UniversityInventors: Atsushi KANEDA, Ken-ichi SHINOHARA, Tetsuhiro NEMOTO
-
Patent number: 10960089Abstract: Described are: [1] a compound represented by the formula (1), [2] a compound containing the compound according to [1] and a target molecule recognition element bonded thereto, [3] a metal complex compound containing one kind of a metal selected from a radioactive metal and a radioactive atom-labeled metal, and the compound according to [1] or [2], which is coordinated to the metal, [4] a drug for preparing a radiolabeled drug, containing the compound according to [1] or [2], [5] use of the compound according to [1] or [2], for producing a radiolabeled drug, [6] a radiolabeled drug containing the metal complex compound according to [3], and [7] a radiodiagnostic imaging agent containing the metal complex compound according to [3]:Type: GrantFiled: February 28, 2017Date of Patent: March 30, 2021Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Yasushi Arano, Tomoya Uehara
-
Publication number: 20210023008Abstract: The invention provides a cationic lipid, a lipid membrane structure containing same, and use thereof. The cationic lipid is represented by the formula (1) wherein R1a, R1b, R2a, R2b, R3a, R3b, Xa, Xb, Ya, Yb, Za, and Zb are as defined in the specification.Type: ApplicationFiled: March 25, 2019Publication date: January 28, 2021Applicants: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Yuta NAKAI, Kota TANGE, Hiroki YOSHIOKA, Shinya TAMAGAWA, Hidetaka AKITA, Hiroki TANAKA, Nae TAKATA, Manami KONISHI, Tatsunari TAKAHASHI
-
Patent number: 10888279Abstract: There is provided a biological information monitoring system for monitoring biological information of a subject on a bed, the system comprising: detectors which detect load of the subject; a center of gravity position calculating unit which acquires temporal variation of a center of gravity position of the subject based on the detected load; a body motion information determining unit which acquires information on body motion of the subject based on the acquired temporal variation; and a respiratory rate calculating unit which calculates a respiratory rate of the subject based on the acquired temporal variation and the information on the body motion of the subject. The body motion information includes information on large and small body motions of the subject, and the body motion information determining unit includes first and second body motion information determining units which determine the information on the large and small body motions of the subject, respectively.Type: GrantFiled: March 27, 2018Date of Patent: January 12, 2021Assignees: MINEBEA MITSUMI INC., NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Hiroyuki Akatsu, Kunihiko Sato, Norihito Iida, Shiroh Isono
-
Patent number: 10865247Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: GrantFiled: February 20, 2020Date of Patent: December 15, 2020Assignees: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20200347390Abstract: [Problem] Provided are a production method for a multi-input/multi-output-type genetic switch or a transcription factor, and a multi-input/multi-output-type genetic switch or a transcription factor. [Solving Means] The inventors of the present invention have completed a production method for a multi-input/multi-output-type genetic switch or a transcription factor, essentially including the steps of “fusing two or more transcription factor genes to each other” and “introducing mutations into the fusion-type transcription factor gene,” and have further succeeded in obtaining a multi-input/multi-output-type genetic switch or a transcription factor by the method.Type: ApplicationFiled: March 23, 2019Publication date: November 5, 2020Applicant: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Daisuke UMENO, Yuki KIMURA, Kyohei OUCHI, Shigeko KAWAI
-
Publication number: 20200310366Abstract: A layer configuration prediction method is provided and includes: a specimen production step of producing multiple specimens by depositing layers of a material in configurations different from each other; a specimen measurement step of performing, on each specimen, measurement to acquire a texture parameter corresponding to a texture; a learning step of causing a computer to perform machine learning of a relation between each of the specimens and the texture parameter; a setting parameter calculation step of calculating a setting parameter corresponding to the texture set to a computer graphics image; and a layer configuration acquisition step of providing the setting parameter as an input to the computer having been caused to perform the machine learning, and acquiring an output representing the layering pattern of layers of the material corresponding to the setting parameter.Type: ApplicationFiled: March 26, 2020Publication date: October 1, 2020Applicants: MIMAKI ENGINEERING CO., LTD., NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Norimichi Tsumura, Junki Yoshii, Keita Hirai, Wataru Arai
-
Publication number: 20200297776Abstract: The purpose of the present invention is to provide a medicament which is useful for prevention or treatment of muscle injury. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to a preventing or therapeutic agent for muscle injury containing the extract as an active ingredient. The preventing or therapeutic agent for muscle injury of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe medicament.Type: ApplicationFiled: June 8, 2020Publication date: September 24, 2020Applicants: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Kazuhide INAGE, Kazuhisa TAKAHASHI, Seiji OHTORI, Sumihisa ORITA
-
Patent number: 10761102Abstract: Provided is a method for derivatizing an s-cis-diene compound with a Cookson-type derivatization reagent, the method including adding, in a reaction stopping step of stopping a derivatization reaction of the s-cis-diene compound, a decomposition inhibitor to inhibit decomposition of a derivative to be obtained.Type: GrantFiled: September 28, 2017Date of Patent: September 1, 2020Assignees: Tokyo University of Science, National University Corporation Chiba University, JEOL Ltd.Inventors: Tatsuya Higashi, Shoujiro Ogawa, Fumio Nomura, Mamoru Satoh, Masaki Takiwaki
-
Patent number: 10759749Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.Type: GrantFiled: August 28, 2017Date of Patent: September 1, 2020Assignees: JCR Pharmaceuticals Co., Ltd., National University Corporation Kone University, National University Corporation Chiba UniversityInventors: Susumu Seino, Kenji Sugawara, Ichiro Mori, Akio Matsumoto, Yoshie Reien
-
Publication number: 20200268913Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.Type: ApplicationFiled: September 26, 2018Publication date: August 27, 2020Applicant: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Yasushi ARANO, Tomoya UEHARA, Hiroyuki SUZUKI
-
Patent number: 10723899Abstract: An object of the present invention is to provide a film which has a high visibility in a solid state and a product which has the film, with a simple material composition. One aspect of the present invention is a film which comprises a core-shell particle which has a core and a shell which covers the core. Moreover, another aspect of the present invention is a product which is covered with the film. Further, another aspect of the present invention is a solution in which core-shell particles are dispersed. The present invention makes it possible to provide a film which has a high visibility in a solid state and a product which has the film, with a simple material composition.Type: GrantFiled: August 24, 2016Date of Patent: July 28, 2020Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Michinari Kohri, Ayaka Kawamura
-
Publication number: 20200199235Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.Type: ApplicationFiled: February 20, 2020Publication date: June 25, 2020Applicants: GeneFrontier Corporation, National University Corporation Chiba UniversityInventors: Kanehisa Kojoh, Akira Miyakoshi, Shizue Katoh, Kumiko Tsuihiji, Yuki Hayami, Mikiko Nakamura, Toshinori Nakayama, Chiaki Iwamura
-
Publication number: 20200149041Abstract: The present invention relates to a guide RNA molecule that hybridizes with a target sequence containing a mutation site of a transforming growth factor ?-induced (TGFBI) gene associated with granular corneal degeneration.Type: ApplicationFiled: June 7, 2018Publication date: May 14, 2020Applicants: The University of Tokyo, National University Corporation Chiba UniversityInventors: Tomohiko Usui, Yukako Taketani, Yasuo Ouchi
-
Publication number: 20200121192Abstract: An image processing apparatus includes a processor including hardware. The processor is configured to: acquire video data; estimate a spatial distribution of a predetermined biological component for which a component spectrum temporally varies with respect to image data of a predetermined frame among a plurality of frames included in the video data; generate biological component video data in which the biological component is extracted from the video data based on the estimated spatial distribution of the biological component in the image data of the predetermined frame; and generate periodic variation video data of the biological component by applying, to the biological component video data, a filter for extracting a predetermined frequency component.Type: ApplicationFiled: December 20, 2019Publication date: April 23, 2020Applicants: OLYMPUS CORPORATION, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Munenori FUKUNISHI, Norimichi TSUMURA, Koki KURITA
-
Patent number: 10557848Abstract: Provided are novel polymer particles for carrying a physiologically active substance and a method of preparing the same. The polymer particles for carrying a physiologically active substance can provide an analytical reagent, which has high analytical precision and sensitivity and can be stably prepared; can easily and precisely control the amount of functional groups carrying the physiologically active substance; can introduce, onto the surface of latex particles, a hydrophilic compound for inhibiting a nonspecific reaction; and can be prepared to have a narrow and uniform particle size distribution.Type: GrantFiled: September 2, 2015Date of Patent: February 11, 2020Assignees: LSI MEDIENCE CORPORATION, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Atsushi Kadowaki, Tatsuo Taniguchi, Yusuke Sasaki, Naho Konishi